AbbVie stock pre-market at EUR 234.20: plus 0.28 percent
Published on 10/05/2026 at 08:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AbbVie stock was at EUR 234.20 pre-market at 8:09 a.m. CEST on October 5, 2026, according to Lang & Schwarz. The price was up 0.28 percent versus the Lang & Schwarz prior close of EUR 233.55 on October 2, 2026.
Pre-market trading
Lang & Schwarz showed a bid of EUR 233.50 and an ask of EUR 234.90 for AbbVie stock. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of AbbVie stock.
RINVOQ approval in the European Union
In a September 22, 2026 release distributed by PR Newswire, AbbVie said the European Commission approved RINVOQ, or upadacitinib, for active polyarticular juvenile idiopathic arthritis in patients aged two years and older who had responded inadequately to, or were intolerant of, one or more disease-modifying antirheumatic drugs. The approval also covers a weight-based oral solution.
Quarterly dividend
AbbVie said in a September 10, 2026 release through PR Newswire that its board declared a quarterly cash dividend of $1.73 per share. The dividend is payable November 16, 2026, to stockholders of record at the close of business on October 15, 2026.
